Christopher Waddick
Förmögenhet: 144 054 $ per 2026-06-30
Förmögenhet: 144 054 $ per 2026-06-30
Christopher J.
Waddick is Chief Financial Officer, Secretary & Director at Cardiol Therapeutics, Inc. since 2022, President & Chief Financial Officer at Active Energy, Inc. since 2013, and President at Nrj Consulting, Inc. since 2009.
Formerly, Mr. Waddick was Chief Financial & Executive Officer at Vasogen, Inc. from 2007 to 2009.
Education includes an MBA from York University and an undergraduate degree from Wilfrid Laurier University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2025-12-30 | 135 900 ( 0,12 % ) | 144 054 $ | 2026-06-30 |
| Företag | Position | Start |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Finansdirektör/CFO | 2018-08-16 |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Supplies natural gas and electricity | Finansdirektör/CFO | 2013-01-01 |
Nrj Consulting, Inc. | President | 2009-11-01 |
| Företag | Position | Slut |
|---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Verkställande Direktör | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 6 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Health Technology |
York University
York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wilfrid Laurier University
Wilfrid Laurier University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Supplies natural gas and electricity | Utilities |
Cardiol Therapeutics, Inc.
Cardiol Therapeutics, Inc. BiotechnologyHealth Technology Operates as a life sciences company that researches and develops antifibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease | Health Technology |
Nrj Consulting, Inc. |
Välj din utgåva
All finansiell information anpassad till den nationella nivån